M.D., Ph.D., Professor, UCSF
Biography
Robert A. Hiatt, M.D., Ph.D., is Professor and former Chair of the Department of Epidemiology and Biostatistics at UCSF, and the Associate Director for Population Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include cancer epidemiology, especially breast cancer, cancer prevention and screening, health services and outcomes research, the social determinants of cancer, and environmental exposures in early life development related to cancer. He was the first Deputy Director of the Division of Cancer Control and Population Sciences at the National Cancer Institute and a past president of the American College of Epidemiology and the American Society for Preventive Oncology. He is Principal Investigator of the NIH All of Us Precision Medicine Initiative at UCSF. He received his medical degree from the University of Michigan and his doctorate in epidemiology from the University of California, Berkeley.
Session Abstract – PMWC 2023 Silicon Valley
Track 2 - January 26 9.00 A.M.-4.30 P.M.
Track Chair:
- Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.
Sessions:
- Clinical Studies Using RWD (PANEL)
Chair: Aaron Kamauu, Navidence
- Liora Schultz, Stanford
- Scott Morris, Optum Life Sciencess
- Sanket Dhurva, UCSF
- Motiur Rahman, FDA
- Farid Vij, Invitae - Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
Chair: Riley Bove, UCSF
- Anna Berry, Sypase
- Matthew Lungren, Microsoft
- Ashley Brenton, Optum
- Vasu Chandrasekaran, Ontada - Data Linkage, Harmonization, and Quality (PANEL)
Chair: Vivek Rudrapatna, UCSF
- Rohit Vashisht, UCSF
- Adam Asare, QLHC
- Dan Riskin, Verantos
- Wanmei Ou, Ontada
- Mindy DeRouen, UCSF
- Using RWE to Uncover and Address Health Disparities (PANEL)
Chair: Chris Boone, AbbVie
- Robert Hiatt, UCSF
- Abasi Ene-Obong, 54gene
- Alice Popejoy, UC Davis Health
- Nuray Yurt, Novartis Oncology
- Vic Spain, Genentech - FDA RWD/RWE Draft and Final Guidances
- Motiur Rahman, FDA
- Fireside Chat:
- Vivek Rudrapatna, UCSF
- Hilary Marston, FDA
- Atul Butte, UCSF - From Real World to Regulatory-Grade: Navigating the Evidence Chasm
Chair: Sheila Walcoff, Goldbug Strategies
- Elaine Katrivanos, Tempus
- Kathy Hibbs, 23andMe
- Mike Ryan, McDermott Will & Emery
- Terry Myerson, Truveta
